Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) (NCT07220629)

🧪 Interventions in This Study

• NT-0796 (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (9 Sites)

• Investigative Site — Mesa, Arizona
• Investigative Site — Hialeah, Florida
• Investigative Site — Jacksonville, Florida
• Investigative Site — Miami, Florida
• Investigative Site — Marrero, Louisiana
• Investigative Site — Columbus, Ohio
• Investigative Site — Seabrook, Texas
• Investigative Site — Salt Lake City, Utah
• Investigative Site — Manassas, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Obesity

• Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools — Tampa, Florida
• SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity — Tucson, Arizona
• Piloting a Patient Navigator Program for Weight Loss — Philadelphia, Pennsylvania
• Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects — Orlando, Florida
• Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans — Pittsburgh, Pennsylvania

Explore by condition: All Obesity clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.